Carrington Laboratories, Inc. and Brookwood Pharmaceuticals, Inc. Extend GelSite(R) Drug Delivery Technology Development
IRVING, Texas, July 20 /PRNewswire-FirstCall/ -- Carrington Laboratories, Inc. today announced that its subsidiary, DelSite Biotechnologies, Inc., extended a joint development agreement with Brookwood Pharmaceuticals, Inc. The goal of this effort is to continue an expanded evaluation of GelSite(R), a DelSite patented drug-delivery technology, as a matrix for injectable applications and for selected classes of drugs. This extension is built on the promising results and evaluations conducted by the joint technical team in the past year.
GelSite(R) polymer is a high-molecular-weight anionic polysaccharide that exhibits distinct chemical and functional properties proprietary to the Company. It is a naturally derived, biocompatible, resorbable biopolymer and is produced under cGMP with high purity at a kilogram scale. This technology has the potential to protect and deliver peptides and proteins effectively while reducing the frequency of drug administration. Fewer injections will improve patient compliance, safety and efficacy. Injectable, controlled- release applications for peptides and proteins are in the multibillion-dollar drug delivery market.
Under this new extended joint development program, the evaluation of GelSite(R) technology will continue to be managed by a team of experts from Brookwood Pharmaceuticals and DelSite. "Brookwood Pharmaceuticals is internationally recognized in the field of drug delivery. The joint scientific team has made progresses in expanding the applications of the GelSite(R) polymer for parenteral delivery of proteins and peptides. We are looking forward to the continued success of this program," said Dr. Carlton E. Turner, president and CEO of Carrington.
About Brookwood Pharmaceuticals
Brookwood Pharmaceuticals, Inc. is a product-focused, drug-delivery company based in Birmingham, Alabama. Brookwood's drug-delivery technologies include long-acting parenteral formulations -- injectable microparticles and injectable solid implants - for the delivery of peptides, small molecules, proteins, nucleic acids, and other biological macromolecules. Brookwood's capabilities include development of physician-administered and self-administered formulations that are effective for days and months following a single administration. Client-partnered development programs begin with evaluation studies, and then proceed to preclinical development, clinical trial manufacturing and commercial manufacturing. Contract manufacturing of clinical supplies and commercial product includes production of drug-delivery formulations such as microparticles, nanoparticles, liposomes, implants, and microparticles of hydrophobic salts. Brookwood's subsidiary, Lakeshore Biomaterials, manufactures biodegradable polymers for drug-delivery products and medical devices. For further information, see http://www.brookwoodpharma.com.
About Carrington
Carrington Laboratories, Inc. is an ISO 9001-certified, research-based, biopharmaceutical and consumer products company currently utilizing naturally-occurring complex carbohydrates to manufacture and market products for mucositis, radiation dermatitis, wound and oral care, as well as to manufacture and market the nutraceutical raw material Manapol(R) and cosmetic raw material Hydrapol(TM). Carrington also manufactures and markets consumer products and manufactures quality products for other companies. Manufacturing operations comply with cGMP standards. Carrington's DelSite Biotechnologies subsidiary is developing its proprietary GelSite(R) technology designed to provide controlled release of peptide and protein-based drugs. Carrington's technology is protected by more than 130 patents in 26 countries. Select products carry the CE mark, recognized by more than 20 countries around the world. For more information, visit http://www.carringtonlabs.com.
Certain statements in this release concerning Carrington may be forward-looking. Actual events will be dependent upon a number of factors and risks including, but not limited to: subsequent changes in plans by the Company's management; delays or problems in formulation, manufacturing, distribution, production and/or launch of new finished products; changes in the regulatory process; changes in market trends; and a number of other factors and risks described from time to time in the Company's filings with the Securities & Exchange Commission, including the Form 10-Q, filed May 15, 2007.
Carrington Laboratories, Inc.CONTACT: Carlton E. Turner, Chief Executive Officer of CarringtonLaboratories, Inc., +1-972-518-1300